© 2021 MJH Life Sciences and Pharmacy Times. All rights reserved.
© 2021 MJH Life Sciences™ and Pharmacy Times. All rights reserved.
February 11, 2016
Disease State Management
New Drug Review
Complera treats HIV infection in previously untreated adults with a viral load of 100,000 copies/mL or less.
The second article in a two-part series examines oncology drug approvals and late-breaking FDA actions.
February 10, 2016
Specialty pharmacies could serve as the primary conduit to generate value from at-risk agreements between manufacturers and providers.
USP may subject pharmacies to both state board and FDA inspections.
The global launch of a new drug requires careful orchestration of sales and marketing support activitiesâ€”a challenge that can have a large financial impact.
February 09, 2016
Industry stakeholders must carefully examine every detail of drug adherence programs to ensure compliance with the Anti-Kickback Statute.
Unique compliance issues may affect specialty pharmacy distribution plans.
New Product Pipeline
Approvals expected for new drugs to treat bladder cancer and advanced ER+ breast canÂcer.
Pharmacists must understand the potential value of biosimilars as a competitive generation of more cost efficient drugs hit the market.
Innovators & Leaders
OptiMed takes a value-driven approach to specialty patient management.
Viewpoints: The Last Word
CRISPR technology may eventually hit the specialty landscape with promising treatments for HIV and cancer.
Lines must be drawn among specialty pharmacies and manufacturers to ensure professional services do not exceed regulatory parameters.
From the Chairman